Understanding a condition requires studying
the biological tissue that it impacts.

Bipolar disorder is a highly complex and heterogeneous disorder, and little is known about its underlying biology. Leveraging human brain tissue from people with bipolar disorder available in existing biobanks, and potentially expanding existing collections over time, will greatly deepen the biological understanding of bipolar disorder and complement genetic findings. 

BD² is pioneering research on existing samples, whose potential for scientific discovery has remained untapped due to insufficient funding. This program will provide unprecedented insight into the underlying mechanisms of bipolar disorder. Developing a molecular brain atlas resource that researchers will use to accelerate scientific understanding.

The CommonMind Consortium, composed of the Icahn School of Medicine at Mount Sinai, the University of Pittsburgh, and the California Institute of Technology, have been selected to develop the BD² Brain Omics Platform.

Open Science

Our commitment to open science invites researchers to access and expand upon new findings, accelerating the process of discovery across the entire bipolar disorder research landscape.